4.2 Article

Personalising laboratory medicine in the 'real world': Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12® (holotranscobalamin) in the diagnosis of vitamin B12 deficiency

Journal

ANNALS OF CLINICAL BIOCHEMISTRY
Volume 58, Issue 5, Pages 445-451

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/00045632211003605

Keywords

Evidence-based medicine; clinical utility; Youden cut-offs; diagnostic uncertainty; electronic test requesting; ‘ real-world’ setting; vitamin B-12

Ask authors/readers for more resources

This study assessed the diagnostic accuracy of serum total B-12 and Active-B-12 (R) in different clinical indications, finding variation in diagnostic performance across indications. The study suggests combining diagnostic accuracy assessments and electronic testing in a 'real-world' setting to evaluate clinical utility by clinical indication, potentially allowing for more personalized laboratory medicine.
Background Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a 'real-world' setting. Methods The diagnostic accuracy of serum total B-12 and Active-B-12 (R) (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B-12 were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m(2). Results Clinical indications included peripheral neuropathy (n = 168), anaemia (n = 168), cognitive decline (n = 125), suspected dietary deficiency (n = 76), other (n = 362). For peripheral neuropathy, the area under the receiver operator curve +/- 95% confidence interval (AUC +/- CI) was 0.63 (0.54-0.71) (P = 0.002) for total B-12 and 0.68 (0.60-0.77) (P < 0.0001) for Active-B-12 (R). For anaemia, AUC +/- CI was 0.56 (0.47-0.66) (P = 0.10) for total B-12 and 0.69 (0.59-0.78) (P < 0.0001) for Active-B-12 (R). For cognitive decline, AUC +/- CI was 0.54 (0.43-0.65) (P = 0.26) for total B-12 and 0.69 (0.58-0.80) (P = 0.0002) for Active-B-12 (R). The pre-post-test change in probability of disease varied by clinical indication. Conclusion Combining diagnostic accuracy studies and electronic testing in a 'real-world' setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B-12 and Active-B-12 (R) varied across all indications. Active-B-12 (R) provided better discrimination, but this may have reflected the cut-offs used.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available